Milbank, Tweed, Hadley & McCloy LLP represented BofA Merrill Lynch, J.P. Morgan, Wells Fargo Securities, Goldman, Sachs & Co., RBC Capital Markets and SunTrust Robinson Humphrey as initial purchasers in connection with the private offering of $350 million aggregate principal amount of USG Corporation’s 5.50% Senior Notes due 2025. In addition, Milbank, Tweed, Hadley & McCloy LLP represented BofA Merrill Lynch as dealer manager in the concurrent cash tender offer for any and all of USG Corporation’s 8.375% Senior Notes due 2018. More >>

Cahill represented the joint book-running managers and co-managers in connection with the Rule 144A offering of $750,000,000 aggregate principal amount of 5% Senior Notes due 2022 by Nielsen Finance LLC and Nielsen Finance Co., a leading global performance management company. Proceeds from the offering will be used for general corporate purposes and to refinance existing indebtedness.

Davis Polk advised underwriters represented by J.P. Morgan Securities LLC and Wells Fargo Securities, LLC in connection with an offering by Kemper Corporation of $250 million aggregate principal amount of its 4.350% senior notes due 2025. More >>

Further adding to its growing corporate transactional practice in New York, Venable LLP announced that it added two top M&A attorneys, Philip T. von Mehren and Michele Maney. They join as partners in the firm’s New York office where Mr. von Mehren will co-chair the New York Corporate Group.

Mr. von Mehren and Ms. Maney join from Baker & McKenzie, where they were also partners. Earlier this month, Venable added cross-border transactional attorney Peter R. Sternberg as a partner in its New York office. More >>

Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. announced they have entered into a definitive agreement for Valeant to acquire Salix for $14.5 billion. Willkie represented Centerview Partners, which served as a financial advisor to Salix, a leader in the gastrointestinal market. More >>

Cadwalader is representing Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), a leading U.S. specialty pharmaceutical company, which today announced a definitive agreement to be acquired by Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) for $158.00 per share, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Salix and Valeant boards of directors and is expected to close in the second quarter of 2015, subject to customary closing conditions and regulatory approval. More >>

Cahill represented Deutsche Bank Securities, BofA Merrill Lynch, Credit Agricole CIB, Fifth Third Securities, Scotiabank, and SunTrust Robinson Humphrey as joint book-running managers and BOC International, BNP PARIBAS, Morgan Stanley, SMBC Nikko, and UBS Investment Bank as co-managers in connection with the Rule 144A offering of $1,800,000,000 aggregate principal amount of 5.50% Senior Notes due 2025 by Wynn Las Vegas, LLC and Wynn Las Vegas Capital Corp., a destination casino resort in Las Vegas, Nevada. More >>